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Abstract
Background: T-type calcium channel activation has been postulated to underlie rhythmicity in the olivo-cerebellar system that is implicated in ET. Ethosuximide
reduces T-type calcium currents and can suppress tremor in two animal models of ET. We explored the effects of ethosuximide in subjects with ET in an open-label
trial using both clinical scales and accelerometric recordings measures. We initially planned to conduct the trial with 15 patients, but due to lack of efficacy and a
high incidence of adverse effects, the trial was stopped after seven patients had participated.
Methods: Seven patients diagnosed with ET were included in the study. The ethosuximide dose was 500 mg daily (BID). The main outcome measures were:
1) tremor clinical rating scale (TCRS) score, 2) accelerometric recordings, and 3) self-reported disability scale score.
Results: Five patients completed the study, and two dropped out due to adverse effects. There were no significant changes in clinical scores in motor task
performance (TCRS 1+2), daily living activities (TCRS 3), or in the patients’ subjective assessment (TCRS 4) and global appraisal. There were no differences
observed for accelerometry data or disability scale scores. Anxiety, nervousness, headache, and dizziness were reported by two patients while on ethosuximide,
causing them to stop the trial. No patient preferred to continue ethosuximide treatment.
Discussion: The results of our exploratory study suggest that ethosuximide is not an effective treatment for ET.
Keywords: Essential tremor, ethosuximide, calcium channel
Citation: Gironell A, Marin-Lahoz J. Ethosuximide for essential tremor: an open-label trial. Tremor Other Hyperkinet Mov. 2016; 6. doi: 10.7916/D8FQ9WN0
* To whom correspondence should be addressed. E-mail: agironell@santpau.cat
Editor: Elan D. Louis, Yale University, USA
Received: March 9, 2016 Accepted: May 5, 2016 Published: July 13, 2016
Copyright: ’ 2016 Gironell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which
permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not
altered or transformed.
Funding: None.
Financial Disclosure: None.
Conflict of Interest: The authors report no conflict of interest.
Ethics Statement: This study was performed in accordance with the ethical standards detailed in the Declaration of Helsinki. The authors’ institutional ethics committee has approved
this study and all patients have provided written informed consent.
Introduction
Essential tremor (ET) is one of the most prevalent neurological
disorders in adults and is the most common tremor disorder. The
etiology, pathophysiology, and exact anatomy of ET remain unclear.
As a consequence, drug treatment for ET remains poor and often
unsatisfactory.1
There is some controversy to whether ET is a neurodegenerative
disease.2 There is considerable evidence in favor of the ‘‘neurodegenera-
tive hypothesis.’’ ET is a progressive disorder of aging associated with cell
loss in the majority of pathologic studies, and there is evidence that
gamma-aminobutyric acid (GABA) system dysfunction plays a role.3,4
The other main theory is the ‘‘olivary hypothesis,’’ in which ET is
the result of a disturbance in the inferior olivary nucleus, an anatomic
structure with inherent oscillatory pacemaking properties.5,6 T-type
calcium channel activation has been postulated to underlie rhythmicity
in the olivo-cerebellar system that is implicated in ET.7,8 Ethosuximide
is a clinical anti-absence seizure medication that reduces T-type
calcium currents.9 This drug was shown to suppress tremor in two
animals model of ET (GABAa alfa1-null and harmaline models).7
We explored the effects of ethosuximide in ET in an open-label trial
using both clinical scales and accelerometric recordings. We initially
planned to conduct the trial with 15 patients, but due to lack of efficacy
and a high incidence of adverse effects, the trial was stopped after
seven patients had participated.
Patient/methods
Seven patients (5 males, 10 females; mean age 74.2 years, range
61 to 77 years) with ET were included in the study (Table 1).
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The diagnosis of ET was established using the Movement Disorders
Society consensus criteria.10 All of them fulfilled the neurophysiolo-
gical criteria of ET.11
The study protocol was approved by the Hospital Ethics
Committee, and informed consent to participate was obtained from
all patients. Exclusion criteria were the presence of psychiatric illness,
hepatic disease, substance abuse, epilepsy, or dystonia. We also
excluded any persons who were professional drivers or operators of
heavy machinery, those taking tremogenic drugs, and if there was a
suspected interaction between ethosuximide and other medications.
Patients were requested to avoid alcohol, caffeine, and smoking for
24 hours before testing.
Three patients were taking propranolol (mean dose: 80 mg daily),
two gabapentin (1,200 mg daily), and two primidone (300 mg daily).
Antitremoric drug dosages were not changed in the month prior to
inclusion or during the trial.
The ethosuximide dose was selected according to the most
frequently used regimen in patients with epilepsy. The starting dose
was 250 mg daily and increased 250 mg weekly up to a maximum of
500 mg daily (BID).
The main outcome measures were: 1) a tremor clinical rating scale
(TCRS),12 2) accelerometric recordings,13 and 3) a self-reported
disability scale.14 A comparison of these measures taken on day 1
(before drug intake) and on day 21 (last dose taken the night before)
was performed. All clinical assessments in all patients were performed
by the same examiner (A.G.).
The TCRS consisted of the scale proposed by Fahn et al.12 with
minimal modifications. Specifically, clinical examination of postural
and kinetic tremor of the hands, legs, head, and trunk (Part 1)
according to the following scale: 0 5 none; 1 5 mild (amplitude
,0.5 cm); 2 5 moderate (amplitude 0.5–1 cm); 3 5 marked
(amplitude 1–2 cm); and 4 5 severe (amplitude . 2 cm) (maximum
score 5 40). Face, tongue, and voice scores were not included.
Measures of motor task performance (Part 2) including handwriting,
drawing spirals (two sizes) and lines, and pouring liquids from one
cup to another were scored as follows: 0 5 normal, 1 5 mildly
abnormal, tremulous; 2 5 moderately abnormal, considerable tremor;
3 5 markedly abnormal; and 4 5 severely abnormal, unable to do the
task (maximum score 5 36). The functional disability rate in daily
living activities (Part 3) including speaking, feeding, bringing liquids to
the mouth, hygiene, dressing, writing, and working was similarly
scored between 0 to 4 (maximum score 5 28). The subjective
assessment by the patient compared to the last visit (Part 4) was scored
as follows: 0 5 no changes, +1 5 slight, +2 5 moderate and +3 5
marked improvement; 21 5 slight, 22 5 moderate, and 23 5
marked worsening. All clinical assessments in all patients were
obtained by the same examiner (A.G.).
Neurophysiologic recordings were assessed as objective tremor
measures with a previously described methodology.13 Briefly, a tri-
axial accelerometer transducer (BIOPAC, USA) was attached to the
dorsal surface of the index finger of the most affected hand. The
patient was comfortably seated upright in a chair. Three 60-s
recordings were obtained in a postural position of arms outstretched
in front of the chest. The hands were allowed to rest for 40 s between
recordings. Tremor was quantified by a power spectra analysis to
determine the dominant frequency peak (Hz) and magnitude of the
accelerometer signal (absolute power of the dominant frequency peak
in mV2) for each axis (x, y, z). Final data of each time-point was the
mean of the three recordings. The study tremor magnitude score was
the great value obtained in one of the three axes.
The self-reported disability scale (Bain et al.)14 consisted of 25
activities of daily living, and each was scored according to the following
scale: 1 5 able to do the activity without difficulty, 2 5 able to do the
activity with a little effort, 3 5 able to do the activity with a lot of
effort, 4 5 unable to do the activity (maximum score 5 100).
Table 1. Clinical Characteristics of Patients in the Present Series
Patient Age, Sex Family
History
Evolution
(years)
ET Medication Completed
Study
Causes of drop-out
1 74, F + 10 Propranolol Yes
2 66, M + 8 Primidone Yes
3 80, F + 5 Primidone No Nervousness, anxiety,
headache
4 79, F + 15 Propranolol No Dizziness, nausea, instability
5 70, F + 20 Propranolol Yes
6 71, M + 15 Gabapentin Yes
7 72. M + 8 Gabapentin Yes
Abbreviations: ET, Essential Tremor; F, Female; M, Male.
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Statistical analysis of medication effects over the main variables was
performed using parametric tests with the exception of TCRS part 4,
which was assessed with nonparametric Wilcoxon matched-pairs tests.
Any p , 0.05 was considered significant.
Results
Five patients completed the study. The results are listed in Table 2.
Pre-hoc power calculation (a 5 0.05) for the full sample of 15 patients
was 90.3%, and post-hoc power for the reduced sample of 5 patients
was 54.3%. There were no significant changes in clinical scores in
motor task performance (TCRS parts 1+2), daily living activities
(TCRS part 3), or the patients’ subjective assessment (TCRS part 4)
and global appraisal. Ethosuximide treatment did not influence the
accelerometry measurements or disability scale scores.
Anxiety, nervousness, headache, and dizziness were reported by two
patients, causing them to stop the trial. No patient preferred to
continue on ethosuximide treatment.
Discussion
This is the first study to investigate the efficacy of ethosuximide in
ET. In this preliminary study, the comparison revealed no significant
improvements in any tremor outcome measures for ethosuximide at
the tested dose.
The power of this pilot study was low due to the small number of
patients who completed the study. However, we think that results are
clinically relevant as none of the patients in this open-label trial
experienced any benefit; therefore they discourage the implementation
of a controlled study with this drug.
Our results are in discordance with the ‘‘olivary hypothesis’’ of ET
and a previous study of ethosuximide in ET animal models.7 The dose
used in the animal study corresponds to the that employed in our
study. Thus, the discrepancy between findings in rats and humans
might be attributable to the imperfection of the ET animal model. In
fact, no existing model exactly recreates all ET features. One of the
main problems is the uncertainty of whether the specific transmitter
abnormalities/central nervous system lesions seen in the animal tremor
model are characteristic of their human counterparts.15
The ability of T-type calcium channel antagonists to suppress
tremor has been investigated in parkinsonian tremor. One study in the
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) monkey model
showed that ethosuximide at doses of 150 mg/day reduced tremor by
60% after 5 days.16 However, negative results were reported for a
pilot study of human parkinsonian tremor that included patients
with Parkinson’s disease (n 5 6) and drug-induced parkinsonian
tremor (n 5 4) at doses of 500 mg/day.17 Only one patient per group
improved, and 80% of the subjects experienced adverse effects
including increased tremor.
Taken together, the results of our exploratory study suggest tat
ethosuximide is not an effective treatment for ET. Research into
developing better ET animal models appears necessary.
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